109 filings
Page 5 of 6
8-K
8a4 p5pkycj
8 Aug 17
Matinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501
12:00am
8-K
y2c0fsoo
26 Jun 17
Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis
12:00am
8-K/A
0ewvgty0nvjkw0wabrz
26 Jun 17
Regulation FD Disclosure
12:00am
8-K
o639k nzeq8
5 Jun 17
Regulation FD Disclosure
12:00am
8-K
wkrblwnwujs7 v6ry
28 Apr 17
Entry into a Material Definitive Agreement
12:00am
8-K
rlrirch 5ncay2ue6h
18 Apr 17
Matinas BioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance
12:00am
8-K
p1xuz0ok6myv
3 Apr 17
Matinas BioPharma Reports 2016 Financial Results and Provides Corporate Update
12:00am
8-K
gelvchafoon15hrn tay
30 Mar 17
Matinas BioPharma Appoints Eric J. Ende, M.B.A, M.D. to its Board of Directors
12:00am
8-K
9tngfvby 3xa7ypv
19 Jan 17
Matinas BioPharma Successfully Completes Warrant Tender Offer– Raises $13.5 Million from Exercise of Warrants
12:00am
8-K
2peui5of7ix0 jp8vbd
21 Dec 16
Entry into a Material Definitive Agreement
12:00am
8-K
8nbb8x
13 Oct 16
Departure of Directors or Certain Officers
12:00am
8-K
dgbdyi 3072gy2e
6 Oct 16
Regulation FD Disclosure
12:00am
8-K
zeq4ud5s2g3lwypp6
13 Sep 16
Matinas BioPharma Completes Private Placement of $8.0 Million
12:00am
8-K
vc1kg8
1 Aug 16
Entry into a Material Definitive Agreement
12:00am
8-K
hn1mt2vc6bsoj53
9 Mar 16
Departure of Directors or Certain Officers
12:00am
8-K
58ir l2funhf4jq9v
5 Nov 15
Submission of Matters to a Vote of Security Holders
12:00am
8-K
fqrl6k
1 Oct 15
Departure of Directors or Certain Officers
12:00am
8-K
ief2vwk34ee g9vbd
9 Sep 15
Regulation FD Disclosure
12:00am
8-K
5uq65smi hoa6k3z
1 Sep 15
Matinas BioPharma Appoints Cochleate Technology Pioneer Raphael J. Mannino, Ph.D., as Senior Vice President and Chief Technology Officer
12:00am
8-K
rvo5x8 jwrn
18 Aug 15
Other Events
12:00am